Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Axial Spondyloarthritis
Recruiting3 awardsPhase 3
Phoenix, Arizona
This trial has two parts. In the first part, people with active axial spondyloarthritis who haven't responded well to other treatments will be given upadacitinib or a placebo. In the second part, people with non-radiographic axial spondyloarthritis will be given the drug or a placebo. The objective is to see if upadacitinib is effective in reducing signs and symptoms, and if it is safe and well-tolerated.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.